On June 8, 2020 Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi (INTASYL) therapeutic platform, reported that it will host a key opinion leader (KOL) call on intratumoral therapy with self-delivering RNAi at 8 a.m. ET on Friday, June 12, 2020 (Press release, Phio Pharmaceuticals, JUN 8, 2020, View Source [SID1234560902]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The call will feature a presentation by KOL Professor Caroline Robert, M.D., Ph.D., of the Gustave Roussy Institute, on the promising new avenues to treat melanoma patients. Surgery combined with adjuvant immunotherapy remains the current standard of care for locally advanced melanoma, however, it is associated with both a high risk of recurrence and significant drug toxicities. Due to these risks, there has been increased interest in novel treatment options such as neoadjuvant immunotherapy and intratumoral immunotherapy. The presentation will include the scientific and clinical rationale for intratumoral neoadjuvant therapy and the role that INTASYL technology can play in such therapeutic approaches. Dr. Robert will also provide an overview of the design for a planned study for the neoadjuvant use of PH-762 administered by intratumoral injection in patients with advanced resectable melanoma. Dr. Robert will be available to answer questions at the conclusion of the call.

In addition, the Phio management team will provide a corporate update on its PH-762 pipeline product as it relates to the planned clinical study. The Company will also discuss recently published data exemplifying that INTASYL based products are ideally suited for novel therapeutic approaches such as neoadjuvant intratumoral immunotherapy.

KOL Call Details:

Topic:

Intratumoral neoadjuvant therapy with self-delivering RNAi

KOL (speaker):

Professor Caroline Robert, M.D., Ph.D., Head of the Dermatology Unit at Gustave
Roussy and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud
University

Date:

Friday, June 12th @ 8am Eastern Time

Dial-in numbers:

1-877-407-4018 (U.S. domestic) / 1-201-689-8471 (international)

Conference ID:

13703530

Webcast:

Click Here for Webcast

Caroline Robert, M.D., Ph.D., is the Head of the Dermatology Unit at Gustave Roussy and co-director of the Melanoma Research Unit at INSERM 981 Paris-Sud University. She trained at the Paris V University, France, and completed a research fellowship at Harvard, Brigham & Women’s hospital in Cancer Immunology and Immunotherapy. She chaired the melanoma group of the European Organization for the Research and Treatment of Cancer (EORTC) from 2014 to 2017 and she is a board member for the European Association of Onco-Dermatology (EADO), the European Society of Medical Oncology (ESMO) (Free ESMO Whitepaper), the European Association of Dermato-Venereology (EADV) the French society of Dermatology and Venereology (SFD), the American Society of Oncology (ASCO) (Free ASCO Whitepaper) and the American Association of Clinical Research (AACR) (Free AACR Whitepaper). Her main focuses of interest are clinical and translational research on melanoma, immunotherapy and targeted therapy, as well as the study of the cutaneous adverse events of anticancer agents. Dr. Robert has coordinated many national and international clinical trials of targeted therapy and immunotherapy for melanoma patients, from phase I to III. She has authored more than 325 articles in peer-reviewed scientific journals, including several publications on new treatments for metastatic melanoma. Her recent work has focused on identification of new biomarkers for immunotherapy and targeted therapies of patients with melanoma.